Monitoring   |   Typical time to onset   |   Management

 

AE management

Monitoring

For early identification and management of AEs, a series of follow-up appointments are recommended. Below is a table displaying the recommended follow-up schedule for patients receiving GIOTRIF® (afatinib) treatment:

Days after start of treatment

Follow-up

Goal

Day 2-3

Phone call or visita

Control for early detection of diarrhoea

Day 7

First follow-up visit

Early control of possible class-effect adverse events (diarrhoea and rash)

Day 30 and every cycle

Monthly
follow-up visit

Monthly follow-up of patient

Days after start of treatment

Day 2-3

Day 7

Day 30 and every cycle

Follow-up

Phone call or visita

First follow-up visit

Monthly
follow-up visit

Goal

Control for early detection of diarrhoea

Early control of possible class-effect adverse events (diarrhoea and rash)

Monthly follow-up of patient

 

aBy an oncologist or an oncology nurse on the basis of the hospital/centre organisation.

Adapted from Arriola E, et al. 2015.1

 


Typical time to onset

Diarrhoea typically has the earliest onset of all common AEs (2-3 days)1

Reported time to AE onset1,2

Chart showing reported time to AE onset

AE management

Common AEs associated with GIOTRIF® (afatinib) treatment are generally well managed with supportive care,3-6 and many of the most common AEs can potentially be managed by dose modification, without compromising efficacy.7-9 For more information on how some of the most common AEs associated with GIOTRIF® (afatinib) use can managed, explore the pages below.


AE=Adverse Event


References

1
Arriola E, et al. Future Oncol. 2015;11(2):267–277.
2
Aw DC, et al. Asia-Pac J Clin Oncol 2018;14(1):23–31.
3
Sequist LV, et al. J Clin Oncol. 2013;31(27):3327–3334.
4
Wu YL, et al. Lancet Oncol 2014;15(2):213–222.
5
Park K, et al. Lancet Oncol 2016;17(5):577–589.
6
Soria JC, et al. Lancet Oncol 2015;16(8):897–890.
7
Yang JC, et al. Ann Oncol 2016;27(11):2103–2110.
8
Hirsh V, et al. First-line afatinib versus gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): patient-reported outcomes and impact of dose modifications on efficacy and adverse events. ASCO. 3–7 June 2016. Chicago, IL, USA. Poster: 369.
9
Halmos B, et al. Lung Cancer 2019;127:103–111.

Back to top

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie policy
I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information about afatinib for non-small-cell lung cancer treatment.

Country-specific product information

Country-specific product information

Click here for country-specific product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.